Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07058012 · ClinicalTrials.gov registry record · Phase 2
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
A Phase 2 study, sponsored by NSABP Foundation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT07058012 is a Phase 2 study that is actively recruiting participants, run by NSABP Foundation. The registered enrollment target is 79 participants.
The verdict
NCT07058012, a Phase 2 study, is actively recruiting participants, sponsored by NSABP Foundation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment. Immunotherapeutic drugs (immunotherapies) act on different proteins on the surface of cells of the immune system and trigger the immune system to destroy cancer cells. The drugs being studied in NSABP FC-13 are cemiplimab, fianlimab, and REGN7075.
Interventions
- DRUG Cemiplimab
- DRUG cemiplimab plus fianlimab
- DRUG cemiplimab + REGN7075
- OTHER ctDNA testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2026-04-17 |
| Est. Completion | 2029-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07058012
The ClinicalTrials.gov registry entry for NCT07058012 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cemiplimab is the first listed.
NCT07058012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07058012 about?
NCT07058012 is a clinical study titled "A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)". The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment. Immunotherapeutic drugs (immunotherapies) act o...
What is the current status of trial NCT07058012?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2026-04-17. Estimated completion is 2029-06-01.
What interventions are being tested in trial NCT07058012?
The interventions under investigation include: Cemiplimab (DRUG), cemiplimab plus fianlimab (DRUG), cemiplimab + REGN7075 (DRUG), ctDNA testing (OTHER).
Who is sponsoring clinical trial NCT07058012?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.